Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study

Simply Wall St.07-26

In July 2026, Alpha Tau Medical reported clinical data showing a 100% objective response rate and encouraging survival outcomes from its Alpha DaRT plus pembrolizumab study in elderly patients with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654637850?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-07-26 16:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654637850","market":"nz","top_or_hot":-1,"title":"Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study","media":"Simply Wall St.","content":"<div>\n<p>In July 2026, Alpha Tau Medical reported clinical data showing a 100% objective response rate and encouraging survival outcomes from its Alpha DaRT plus pembrolizumab study in elderly patients with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-down-77-after-reporting-100-respon\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-26 16:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-down-77-after-reporting-100-respon><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In July 2026, Alpha Tau Medical reported clinical data showing a 100% objective response rate and encouraging survival outcomes from its Alpha DaRT plus pembrolizumab study in elderly patients with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-down-77-after-reporting-100-respon\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DRTS","symbol_name":"Alpha Tau Medical","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-down-77-after-reporting-100-respon","article_id":"2654637850","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/alpha-tau-medical-drts-is-down-77-after-reporting-100-respon","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2654637850","pubTimestamp":1785054235,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In July 2026, Alpha Tau Medical reported clinical data showing a 100% objective response rate and encouraging survival outcomes from its Alpha DaRT plus pembrolizumab study in elderly patients with advanced head and neck squamous cell carcinoma, with minimal Alpha DaRT-related toxicity and results presented at a major international cancer conference.\nThe trial met its pre-specified success threshold under a Simon two-stage adaptive design, allowing early completion of enrollment after more...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DRTS":"Alpha Tau Medical","BK4082":"医疗保健设备"},"translate_title":"Alpha Tau Medical (DRTS) 在 Alpha DaRT Combo 研究中报告 100% 缓解后下跌 7.7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRTS":1.5},"content_text":"In July 2026, Alpha Tau Medical reported clinical data showing a 100% objective response rate and encouraging survival outcomes from its Alpha DaRT plus pembrolizumab study in elderly patients with advanced head and neck squamous cell carcinoma, with minimal Alpha DaRT-related toxicity and results presented at a major international cancer conference. The trial met its pre-specified success threshold under a Simon two-stage adaptive design, allowing early completion of enrollment after more than six responders, underscoring how a small single-center study can still yield clinically meaningful signals in a difficult-to-treat population. We’ll now examine how the strong objective response rate in combination with pembrolizumab could shape Alpha Tau Medical’s broader investment narrative. AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementWhat Is Alpha Tau Medical's Investment Narrative?For Alpha Tau, being a shareholder really comes down to believing that Alpha DaRT can convert today’s early clinical signals into tomorrow’s commercial products across several hard-to-treat cancers, before the company’s cash runway and dilution risk catch up with it. The new head and neck data, with a 100% objective response rate alongside pembrolizumab, clearly strengthens the near-term catalyst set by adding another potential combo story to the ongoing pivotal cSCC program, GBM REGAIN trial and growing pancreatic portfolio. That said, the trial’s tiny, single-center design and the absence of revenue mean the market may treat this as hypothesis-generating rather than thesis-changing, at least until larger datasets or regulatory milestones follow, which leaves execution risk, valuation and funding needs as the central questions. However, investors also need to consider how ongoing losses and dilution risk could influence outcomes.\n\nAccording our valuation report, there's an indication that Alpha Tau Medical's share price might be on the expensive side.Exploring Other PerspectivesDRTS 1-Year Stock Price Chart The Simply Wall St Community’s single fair value estimate sits at US$14.20, reflecting one clear-cut viewpoint. By contrast, recent trial successes, cash burn and dilution risk give you plenty of reasons to weigh alternative scenarios for Alpha Tau’s longer term performance.Explore another fair value estimate on Alpha Tau Medical - why the stock might be worth as much as 14% more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Alpha Tau Medical research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.Our free Alpha Tau Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alpha Tau Medical's overall financial health at a glance.Searching For A Fresh Perspective?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Outshine the giants: these 17 early-stage AI stocks could fund your retirement.The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Uncover the next big thing with 20 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654637850","isCrawlerRequest":true}